Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 41Prostatic Neoplasms 32Ovarian Neoplasms 23Testicular Neoplasms 18Carcinoma, Transitional Cell 16Carcinoma, Renal Cell 16Carcinoma, Non-Small-Cell Lung 15Neoplasms 13Melanoma 13Testicular Germ Cell Tumor 12Colorectal Neoplasms 12Breast Neoplasms 12Neoplasm Metastasis 10Urethral Neoplasms 9Stomach Neoplasms 9Lung Neoplasms 9Endodermal Sinus Tumor 9Teratoma 8Pancreatic Neoplasms 8Central Nervous System Neoplasms 8Carcinoma, Embryonal 8Carcinoma, Ovarian Epithelial 7Triple Negative Breast Neoplasms 6Seminoma 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Esophageal Neoplasms 5Endometrial Neoplasms 5Penile Neoplasms 4

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Urothelial Carcinoma × Paclitaxel × Genitourinary × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡